We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Still on the edge

6 February 2014 By Neil Unmack

The UK pharma group says patent expiries will hit earnings harder than analysts expected. Management sees growth returning in 2017, but rivals like Sanofi offer a less risky earnings trajectory. After a good run in recent months, AstraZeneca’s shares are taking a lot on trust.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)